Skip to main content
Erschienen in: Familial Cancer 4/2019

17.06.2019 | Original Article

Ability of known susceptibility SNPs to predict colorectal cancer risk for persons with and without a family history

verfasst von: Mark A. Jenkins, Aung K. Win, James G. Dowty, Robert J. MacInnis, Enes Makalic, Daniel F. Schmidt, Gillian S. Dite, Mirosl Kapuscinski, Mark Clendenning, Christophe Rosty, Ingrid M. Winship, Jon D. Emery, Sibel Saya, Finlay A. Macrae, Dennis J. Ahnen, David Duggan, Jane C. Figueiredo, Noralane M. Lindor, Robert W. Haile, John D. Potter, Michelle Cotterchio, Steven Gallinger, Polly A. Newcomb, Daniel D. Buchanan, Graham Casey, John L. Hopper

Erschienen in: Familial Cancer | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Before SNP-based risk can be incorporated in colorectal cancer (CRC) screening, the ability of these SNPs to estimate CRC risk for persons with and without a family history of CRC, and the screening implications need to be determined. We estimated the association with CRC of a 45 SNP-based risk using 1181 cases and 999 controls, and its correlation with CRC risk predicted from detailed family history. We estimated the predicted change in the distribution across predefined risk categories, and implications for recommended screening commencement age, from adding SNP-based risk to family history. The inter-quintile risk ratio for colorectal cancer risk of the SNP-based risk was 3.28 (95% CI 2.54–4.22). SNP-based and family history-based risks were not correlated (r = 0.02). For persons with no first-degree relatives with CRC, screening could commence 4 years earlier for women (5 years for men) in the highest quintile of SNP-based risk. For persons with two first-degree relatives with CRC, screening could commence 16 years earlier for men and women in the highest quintile, and 7 years earlier for the lowest quintile. This 45 SNP panel in conjunction with family history, can identify people who could benefit from earlier screening. Risk reclassification by 45 SNPs could inform targeted screening for CRC prevention, particularly in clinical genetics settings when mutations in high-risk genes cannot be identified. Yet to be determined is cost-effectiveness, resources requirements, community, patient and clinician acceptance, and feasibility with potentially ethical, legal and insurance implications.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Win AK, Ait Ouakrim D, Jenkins MA (2014) Risk profiling: familial colorectal cancer. Cancer Forum 38(1):15–25 Win AK, Ait Ouakrim D, Jenkins MA (2014) Risk profiling: familial colorectal cancer. Cancer Forum 38(1):15–25
10.
Zurück zum Zitat Hopper JL, Carlin JB (1992) Familial aggregation of a disease consequent upon correlation between relatives in a risk factor measured on a continuous scale. Am J Epidemiol 136(9):1138–1147CrossRef Hopper JL, Carlin JB (1992) Familial aggregation of a disease consequent upon correlation between relatives in a risk factor measured on a continuous scale. Am J Epidemiol 136(9):1138–1147CrossRef
13.
Zurück zum Zitat Howlader N, Noone A, Krapcho M, Garshell J, Miller D, Altekruse S et al (eds) (2014) SEER cancer statistics review, 1975-2011. Bethesda, National Cancer Institute Howlader N, Noone A, Krapcho M, Garshell J, Miller D, Altekruse S et al (eds) (2014) SEER cancer statistics review, 1975-2011. Bethesda, National Cancer Institute
15.
Zurück zum Zitat StataCorp (2015) Stata statistical software: release 14. StataCorp LP, College Station StataCorp (2015) Stata statistical software: release 14. StataCorp LP, College Station
17.
Zurück zum Zitat Dite GS, MacInnis RJ, Bickerstaffe A, Dowty JG, Allman R, Apicella C et al (2016) Breast cancer risk prediction using clinical models and 77 independent risk-associated SNPs for women aged under 50 years: Australian Breast Cancer Family Registry. Cancer Epidemiol Biomark Prev 25(2):359–365. https://doi.org/10.1158/1055-9965.EPI-15-0838 CrossRef Dite GS, MacInnis RJ, Bickerstaffe A, Dowty JG, Allman R, Apicella C et al (2016) Breast cancer risk prediction using clinical models and 77 independent risk-associated SNPs for women aged under 50 years: Australian Breast Cancer Family Registry. Cancer Epidemiol Biomark Prev 25(2):359–365. https://​doi.​org/​10.​1158/​1055-9965.​EPI-15-0838 CrossRef
19.
Zurück zum Zitat Tenesa A, Dunlop MG (2009) New insights into the aetiology of colorectal cancer from genome-wide association studies. Nat Rev Genet 10(6):353–358CrossRef Tenesa A, Dunlop MG (2009) New insights into the aetiology of colorectal cancer from genome-wide association studies. Nat Rev Genet 10(6):353–358CrossRef
23.
Zurück zum Zitat Antoniou AC, Pharoah PDP, McMullan G, Day NE, Ponder BAJ, Easton D (2001) Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study. Genet Epidemiol 21(1):1–18CrossRef Antoniou AC, Pharoah PDP, McMullan G, Day NE, Ponder BAJ, Easton D (2001) Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study. Genet Epidemiol 21(1):1–18CrossRef
24.
Zurück zum Zitat Cannings C, Thompson E, Skolnick M (1978) Probability functions on complex pedigrees. Adv Appl Prob 10(1):26–61CrossRef Cannings C, Thompson E, Skolnick M (1978) Probability functions on complex pedigrees. Adv Appl Prob 10(1):26–61CrossRef
25.
Zurück zum Zitat Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M et al (eds) (2007) Cancer incidence in five continents, vol IX. International Agency for Research on Cancer, Lyon Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M et al (eds) (2007) Cancer incidence in five continents, vol IX. International Agency for Research on Cancer, Lyon
26.
Zurück zum Zitat Pharoah PDP, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BAJ (2002) Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 31(1):33–36CrossRef Pharoah PDP, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BAJ (2002) Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet 31(1):33–36CrossRef
27.
Zurück zum Zitat Wentzensen N, Wacholder S (2013) From differences in means between cases and controls to risk stratification: a business plan for biomarker development. Cancer Discov 3(2):148–157CrossRef Wentzensen N, Wacholder S (2013) From differences in means between cases and controls to risk stratification: a business plan for biomarker development. Cancer Discov 3(2):148–157CrossRef
Metadaten
Titel
Ability of known susceptibility SNPs to predict colorectal cancer risk for persons with and without a family history
verfasst von
Mark A. Jenkins
Aung K. Win
James G. Dowty
Robert J. MacInnis
Enes Makalic
Daniel F. Schmidt
Gillian S. Dite
Mirosl Kapuscinski
Mark Clendenning
Christophe Rosty
Ingrid M. Winship
Jon D. Emery
Sibel Saya
Finlay A. Macrae
Dennis J. Ahnen
David Duggan
Jane C. Figueiredo
Noralane M. Lindor
Robert W. Haile
John D. Potter
Michelle Cotterchio
Steven Gallinger
Polly A. Newcomb
Daniel D. Buchanan
Graham Casey
John L. Hopper
Publikationsdatum
17.06.2019
Verlag
Springer Netherlands
Erschienen in
Familial Cancer / Ausgabe 4/2019
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI
https://doi.org/10.1007/s10689-019-00136-6

Weitere Artikel der Ausgabe 4/2019

Familial Cancer 4/2019 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.